Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

TOKYO – October 29, 2026 -- The Global Health Innovative Technology (GHIT) Fund has committed about JPY 1.06 billion (USD 6.8 million) to nine R&D projects covering drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NTDs) and emerging infectious diseases such as Ebola.

STOCKHOLM – September 04, 2026 -- Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease, BioArctic AB's partner Eisai announced.